Restoring TGFβ function in microsatellite unstable (MSI-H) colorectal cancer reduces tumourigenicity but increases metastasis formation

被引：0
|
作者：
Janindra Warusavitarne
Fiona McDougall
Keshani de Silva
Rebecca Barnetson
Marinella Messina
Bruce G. Robinson
Margaret Schnitzler
机构：
[1] Royal North Shore Hospital and University of Sydney,Department of Cancer Genetics, Kolling Institute of Medical Research
[2] Royal North Shore Hospital,Department of Anatomical Pathology, PaLMS
来源：
International Journal of Colorectal Disease | 2009年 / 24卷
关键词：
Microsatellite instability; TGFβ; Metastasis; Colorectal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：139 / 144
页数：5
相关论文
共 50 条
  • [41] Combination of nivolumab (nivo) 1 ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study
    Lonardi, S.
    Andre, T.
    Wong, K. Y. M.
    Morse, M.
    McDermott, R.
    Hill, A.
    Hendlisz, A.
    Lenz, H.
    Leach, J.
    Moss, R. A.
    Cao, Z. A.
    Ledeine, J.
    Kopetz, S.
    Overman, M.
    ANNALS OF ONCOLOGY, 2017, 28 : 3 - 3
  • [42] Combination of nivolumab (nivo) plus ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.
    Andre, Thierry
    Lonardi, Sara
    Wong, Ka Yeung Mark
    Morse, Michael
    McDermott, Raymond S.
    Hill, Andrew Graham
    Hendlisz, Alain
    Lenz, Heinz-Josef
    Leach, Joseph W.
    Moss, Rebecca Anne
    Cao, Z. Alexander
    Ledeine, Jean-Marie
    Chan, Emily
    Kopetz, Scott
    Michael, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] SAFETY PROFILE OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH DNA MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH (DMMR/MSI-H) METASTATIC COLORECTAL CANCER (MCRC) IN CHECKMATE-142
    Brutcher, Edith
    Khoukaz, Taline
    Hartman, Leighanne
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [44] NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR/MSI-H Immunotherapy (COMMIT) Study: A Randomized Phase 3 Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination vs Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (NCT02997228).
    不详
    ONCOLOGY-NEW YORK, 2021, 35 (06): : 367 - 367
  • [45] Targeted treatment (TT) after immune checkpoint inhibitors (ICIs) in BRAF V600E mutated (BRAFm) and deficient mismatch repair or microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC)
    Ambrosini, M.
    Tougeron, D.
    Modest, P.
    Guimbaud, R.
    Kopetz, S.
    Decraecker, M.
    Sclafani, F.
    Coutzac, C.
    Lievre, A.
    Alouani, E. L.
    Marmorino, F.
    Pernot, S.
    Sinicrope, A.
    Elez Fernandez, E.
    Germani, M. M.
    Pietrantonio, F.
    Lonardi, S.
    Parent, P.
    Gallois, C.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S32 - S32
  • [46] Nivolumab in patients with DNA mismatch repairdeficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.
    Overman, Michael J.
    Bergamo, Francesca
    McDermott, Raymond S.
    Aglietta, Massimo
    Chen, Franklin
    Gelsomino, Fabio
    Wong, Mark
    Morse, Michael
    Van Cutsem, Eric
    Hendlisz, Alain
    Neyns, Bart
    Moss, Rebecca Anne
    Zhao, Huanyu
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [47] Molecular and immune landscape by cyclin dependent kinase (CDK) 4/6 expression and TP53 mutational status in mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC).
    Wong, Alexandra
    Gandhi, Nishant
    Xiu, Joanne
    Algaze, Sandra
    Jayachandran, Priya
    Ashouri, Karam
    Soni, Shivani
    Zhang, Wu
    Lo, Jae Ho
    Mittal, Pooja
    Torres-Gonzalez, Lesly
    Weinberg, Benjamin Adam
    Lou, Emil
    Goel, Sanjay
    Yu, Jian
    Zhang, Lin
    Battaglin, Francesca
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 190 - 190
  • [48] Nivolumab plus ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.
    Andre, Thierry
    Lonardi, Sara
    Wong, Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Moss, Rebecca Anne
    Ledeine, Jean-Marie
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [49] A phase 3 study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
    Andre, T.
    Van Cutsem, E.
    Elez, E.
    Bennouna, J.
    de la Fouchardiere, C.
    Yoshino, T.
    Jensen, L.
    Mendez, G.
    Li, J.
    Goekkurt, E.
    Abdullaev, S.
    Chen, T.
    Lei, M.
    Lonardi, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S250 - S250
  • [50] Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)
    Lenz, H-J. J.
    Van Cutsem, E.
    Limon, M. L.
    Wong, K. Y.
    Hendlisz, A.
    Aglietta, M.
    Garcia-Alfonso, P.
    Neyns, B.
    Luppi, G.
    Cardin, D.
    Dragovich, T.
    Shah, U.
    Atasoy, A.
    Postema, R.
    Boyd, Z.
    Ledeine, J-M.
    Overman, M.
    Lonardi, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 714 - 714
12345